ciclosporin

(redirected from Cyclosporins)
Also found in: Medical.

ci·clo·spor·in

 (sī′klə-spôr′ĭn)
n.
Variant of cyclosporine.

ciclosporin

(ˌsaɪkləʊˈspɔːrɪn) or

cyclosporin

n
(Pharmacology) a drug extracted from a fungus and used after organ transplantation to suppress the body's immune mechanisms, and so prevent rejection of an organ
Mentioned in ?
References in periodicals archive ?
Thermospray high-performance liquid chromatography/mass spectrometric determination of cyclosporins.
Cyclosporin A (CsA) [3] is a powerful immunosuppressive drug used primarily in solid organ and bone marrow transplantation but increasingly in conditions such as multiple sclerosis, eczema, psoriasis, and asthma (1).
Previously reported methods for MS analysis of CsA have used structural analogs of CsA [cyclosporin C (12,13) and cyclosporin D (CsD) (16-18)] as internal reference compounds for quantifying CsA.
Thus, 10 cyclophilins wind up facing outward, with 10 cyclosporins sandwiched between them.
Cyclosporin works by first attaching to a protein called cyclophilin.
Cyclosporins protect damaged neurons from dying, and have been shown to be potent neuroprotectants in models of acute brain attack including stroke, traumatic brain and spinal cord injury, and also the chronic neurodegenerative diseases of Alzheimer's, Parkinson's, Huntington's and ALS.
The first presentation "Brain-derived respiring mitochondria exhibit homogeneous, complete and cyclosporin-sensitive permeability transition" demonstrated that cyclosporin protects metabolically active brain mitochondria in particular, information important to demonstrating the mechanism by which cyclosporin protects the brain.
Cyclosporins protect the brain mitochondria and prevent neuron death in stroke, traumatic brain injury, spinal cord injury, Alzheimer disease, Parkinson disease, Huntington disease and amyotrophic lateral sclerosis (ALS) animal models.
Maas BiolAB is a privately held neuropharmaceutical corporation developing cyclosporin formulations and with industry partners discovering novel, improved neuroprotective cyclosporin analogs.
Maas scientists and biotechnology partners are creating new generations of improved neuroprotectant cyclosporins, analogs and formulations.
Maas BiolAB has been granted Cyclosporin Neuroprotection patent number 291 233 by the Czech Republic Patent Office.
Cyclosporin is effective in preventing brain damage in animal models of sudden onset brain disease, including embolic stroke, global ischemia after CPR rescue from heart attack, traumatic brain injury, and spinal cord injury.